公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20240028790A1

公开(公告)日：2024-01-25

申请号：US18256442

申请日：2021-12-22

Applicant: AMGEN INC. ,  Board of Regents, The University of Texas System

Inventor： Tian Wu ,  Michael Schneider ,  Ryan Khalaf ,  Hugh Smyth ,  Ashlee Brunaugh ,  Li Ding

IPC: G06F30/20

CPC classification number: G06F30/20

Abstract: A forecasting modeling computing system includes a processors and a memory including a set of computer-executable instructions that, when executed by the processor, cause the forecasting modeling computing system to receive design parameters, determine a predicted median particle size, identify a predictive quadratic model, and display a response surface visualization. A computer-implemented method includes receiving design parameters, determining a predicted median particle size, identifying a predictive quadratic model; and display a response surface visualization.

公开(公告)号：US20240024579A1

公开(公告)日：2024-01-25

申请号：US18374288

申请日：2023-09-28

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon Moberg

IPC: A61M5/20 ,  A61M5/24 ,  A61M5/32

CPC classification number: A61M5/20 ,  A61M5/24 ,  A61M5/3243 ,  A61M2005/2013 ,  A61M5/3202

Abstract: A device, method, and system for drug delivery includes a casing for housing a drug storage container, the drug storage container including a dose delivery member, at least a portion of the dose delivery member extending through an opening in the casing; a guard movable relative to the casing between extended and retracted positions, the portion of the dose delivery member being surrounded by the guard in the extended position and the portion of the dose delivery member being at least partially exposed when the guard is in the retracted position; an interference arrangement for providing selected threshold of resistance to movement of the guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the detent arrangement having a first member associated with a surface within the casing, and a second member extending from the guard, the first and second members engaging one another to retain the guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another to allow the guard to move into the retracted position when the device is pressed toward the injection site during insertion of the dose delivery member.

公开(公告)号：US11873343B2

公开(公告)日：2024-01-16

申请号：US17529794

申请日：2021-11-18

Applicant: AMGEN INC.

Inventor： Stephen Robert Brych ,  Lyanne M. Wong ,  Jaymille Fallon ,  Monica Michelle Goss ,  Jian Hua Gu ,  Pavan K. Ghattyvenkatakrishna

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76

Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

公开(公告)号：US11872374B2

公开(公告)日：2024-01-16

申请号：US16951987

申请日：2020-11-18

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon Moberg

IPC: A61M5/20 ,  A61M5/24 ,  A61M5/32

CPC classification number: A61M5/20 ,  A61M5/24 ,  A61M5/3243 ,  A61M5/3202 ,  A61M2005/2013

Abstract: A device and method for drug delivery includes a casing for housing a drug storage container, the container including a dose delivery member, at least a portion of the dose delivery member extending through an opening in the casing; a guard movable relative to the casing between extended and retracted positions; an interference arrangement for providing selected threshold of resistance to movement of the guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the arrangement having a first member and a second member, the first and second members engaging one another to retain the guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another to allow the guard to move into the retracted position.

公开(公告)号：US11866508B2

公开(公告)日：2024-01-09

申请号：US17142850

申请日：2021-01-06

Applicant: AMGEN INC.

Inventor： William Christian Fanslow, III ,  Carl Kozlosky ,  Jean Gudas

IPC: A61K39/00 ,  C07K16/30 ,  C07K16/46 ,  G01N33/68 ,  C07K16/28

CPC classification number: C07K16/30 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/3046 ,  C07K16/468 ,  G01N33/6893 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.

公开(公告)号：US20240002545A1

公开(公告)日：2024-01-04

申请号：US18252442

申请日：2021-11-09

Applicant: AMGEN INC.

Inventor： Timothy RILEY ,  Fernando GARCES ,  Zhulun WANG ,  Bram Estes ,  Darren L. Bates

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/31

Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.

公开(公告)号：US20230405040A1

公开(公告)日：2023-12-21

申请号：US18035198

申请日：2021-11-04

Applicant: AMGEN INC.

Inventor： Winnie SOHN ,  Zachary JONES ,  Helina KASSAHUN

IPC: A61K31/713 ,  C12N15/113 ,  A61K47/54 ,  A61K9/00 ,  A61P3/06

CPC classification number: A61K31/713 ,  C12N15/113 ,  A61K47/549 ,  A61K9/0012 ,  A61P3/06

Abstract: The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles. In particular, the present invention relates to methods for reducing serum Lp(a) levels and reducing the risk of cardiovascular events in patients with elevated levels of Lp(a) comprising administering an LPA-targeted RNAi construct according to specific dosage regimens. Pharmaceutical compositions comprising the LPA-targeted RNAi constructs for use in the methods are also disclosed.

公开(公告)号：US20230398147A1

公开(公告)日：2023-12-14

申请号：US18026505

申请日：2021-09-15

Applicant: AMGEN INC. ,  AMGEN RESEARCH (MUNICH) GmbH

Inventor： Adam B. MCCULLOUGH ,  Hosein KOUROS-MEHR ,  Peter KUFER ,  Mark SALVATI ,  Alexander C. MINELLA ,  Dirk NAGORSEN ,  Vijay UPRETI ,  Mukul MINOCHA ,  Brett HOUK

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  C07K14/81 ,  A61K39/00

CPC classification number: A61K35/17 ,  C07K16/2809 ,  A61P35/00 ,  C07K14/8103 ,  A61K39/4611 ,  C12Y304/17021 ,  A61K2239/13 ,  A61K2239/58 ,  A61K2239/38 ,  A61K2239/31

Abstract: The present invention relates to methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer in a patient. The administration methods reduce the incidence and/or severity of adverse events, such as cytokine release syndrome, and entail administering to a patient a priming dose of the bispecific T-cell engaging molecule by continuous intravenous infusion over a period of days followed by administration of a therapeutic dose of the bispecific T-cell engaging molecule by a bolus intravenous infusion at dosing intervals of at least a week.

公开(公告)号：US20230381424A1

公开(公告)日：2023-11-30

申请号：US18032396

申请日：2021-11-01

Applicant: AMGEN INC.

Inventor： Carsten Bech ,  Jakob Halkjaer Pedersen ,  Joshua Jay Dudman ,  Adrianus Gerardus Verschuren ,  Chiushun Dan

IPC: A61M5/32

CPC classification number: A61M5/3287 ,  A61M2205/581

Abstract: A drug delivery device assembly is provided, including an injector housing, a needle assembly, a drive assembly, and a dose feedback accessory. The injector housing may include a body with a proximal end, a distal end, a longitudinal axis extending between the proximal end and the distal end, and at least one window. The needle assembly is at least partially disposed within the body and may include a syringe barrel containing a medicament, a plunger stopper disposed in the syringe barrel, and a needle or a cannula. The drive assembly is at least partially disposed within the body and operably coupled with the needle assembly to urge the medicament through the needle or cannula during an injection sequence. The dose feedback accessory includes an accessory body configured to be selectively coupled with the injector housing and a feedback indicator configured to convey to a user information relating to an injection status event.